Global epidemiology of hepatitis C virus infection, The Lancet Infectious Diseases, vol.5, issue.9, pp.558-567, 2005. ,
DOI : 10.1016/S1473-3099(05)70216-4
Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials, Hepatology, vol.285, issue.1, pp.1176-1184, 2010. ,
DOI : 10.1002/hep.23504
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy, Science, vol.282, issue.5386, pp.103-107, 1998. ,
DOI : 10.1126/science.282.5386.103
Review article: predicting response in hepatitis C virus therapy, Alimentary Pharmacology and Therapeutics, vol.129, issue.1, pp.1043-54, 2006. ,
DOI : 10.1136/gut.52.12.1784
Pharmacodynamics of PEG-IFN ?? differentiate HIV/HCV coinfected sustained virological responders from nonresponders, Hepatology, vol.40, issue.5, pp.943-953, 2006. ,
DOI : 10.1002/hep.21136
On Identifiability of Nonlinear ODE Models and Applications in Viral Dynamics, SIAM Review, vol.53, issue.1, 2010. ,
DOI : 10.1137/090757009
An Effective Automatic Procedure for Testing Parameter Identifiability of HIV/AIDS Models, Bulletin of Mathematical Biology, vol.238, issue.2, pp.11-538, 1007. ,
DOI : 10.1007/s11538-010-9588-2
Identifiability of nonlinear systems with application to HIV/AIDS models, IEEE Transactions on Automatic Control, vol.48, issue.2, pp.330-336, 2003. ,
DOI : 10.1109/TAC.2002.808494
Parameter Identifiability and Estimation of HIV/AIDS Dynamic Models, Bulletin of Mathematical Biology, vol.48, issue.2, pp.785-799, 2008. ,
DOI : 10.1007/s11538-007-9279-9
Design of population studies of hiv dynamics Deterministic and stochastic models of AIDS epidemics and HIV infections with intervention, 2005. ,
Practical Identifiability of HIV Dynamics Models, Bulletin of Mathematical Biology, vol.48, issue.8, pp.2493-2513, 2007. ,
DOI : 10.1007/s11538-007-9228-7
URL : https://hal.archives-ouvertes.fr/inserm-00204273
Modeling and Estimation of Kinetic Parameters and??Replicative Fitness of??HIV-1 from??Flow-Cytometry-Based Growth Competition??Experiments, Bulletin of Mathematical Biology, vol.48, issue.3, pp.1749-1771, 2008. ,
DOI : 10.1007/s11538-008-9323-4
Maximum Likelihood Estimation of Long-Term HIV Dynamic Models and Antiviral Response, Biometrics, vol.48, issue.1 ,
DOI : 10.1111/j.1541-0420.2010.01422.x
URL : https://hal.archives-ouvertes.fr/inserm-00486937
Optimal design in random-effects regression models, Biometrika, vol.84, issue.2, pp.429-442, 1997. ,
DOI : 10.1093/biomet/84.2.429
Fisher information matrix for nonlinear mixed effects multiple response models: Evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model, Statistics in Medicine, vol.60, issue.14, pp.1940-1956, 2009. ,
DOI : 10.1111/j.0006-341X.2004.00148.x
URL : https://hal.archives-ouvertes.fr/inserm-00371363
Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0. computer methods and programs in biomedicine, pp.55-65, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00431457
Antiviral action of ribavirin in chronic hepatitis C, Gastroenterology, vol.126, issue.3, pp.703-714, 2004. ,
DOI : 10.1053/j.gastro.2003.12.002
Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin, Hepatology, vol.30, issue.6, pp.1343-1350, 2003. ,
DOI : 10.1053/jhep.2003.50217
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection, Nature, vol.23, issue.7019, pp.922-924, 2005. ,
DOI : 10.1086/315661
The kinetics of hepatitis C virus, European Journal of Gastroenterology & Hepatology, vol.18, issue.4, pp.85-90, 2000. ,
DOI : 10.1097/00042737-200604000-00006
A perspective on modeling hepatitis C virus infection, Journal of Viral Hepatitis, 2010. ,
Optimum Experimental Design, 1992. ,
DOI : 10.1007/978-3-642-04898-2_434
Design in nonlinear mixed effects models: Optimization using the Fedorov???Wynn algorithm and power of the Wald test for binary covariates, Statistics in Medicine, vol.39, issue.28, pp.5162-79, 2007. ,
DOI : 10.1002/sim.2910
URL : https://hal.archives-ouvertes.fr/hal-00263513
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C, Journal of Hepatology, vol.43, issue.2, pp.250-257, 2005. ,
DOI : 10.1016/j.jhep.2005.05.016
Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients, Gastroenterology, vol.128, issue.2, pp.313-340, 2005. ,
DOI : 10.1053/j.gastro.2004.11.059
Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon, Hepatology, vol.27, issue.6, pp.1351-1358, 2003. ,
DOI : 10.1053/jhep.2003.50218
Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon ??2a, Gastroenterology, vol.120, issue.6, pp.1438-1447, 2001. ,
DOI : 10.1053/gast.2001.24006
Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study, Antiviral Therapy, vol.9, pp.491-498, 2004. ,
Pharmacodynamics of peg-ifn alpha-2a in hiv/hcv co-infected patients: Implications for treatment outcomes, Journal of Hepatology, 2010. ,
Maximum likelihood estimation in nonlinear mixed effects models, Computational Statistics & Data Analysis, vol.49, issue.4, pp.1020-1038, 2005. ,
DOI : 10.1016/j.csda.2004.07.002
Relative curvature measures of nonlinearity, Journal of the Royal Statistical Society. Series B (Methodological), pp.1-25, 1980. ,
Deterministic and stochastic models of AIDS epidemics and HIV infections with intervention, World Scientific, 2005. ,
DOI : 10.1142/5737
Constructing optimal designs for fitting pharmacokinetic models, Statistics and Computing, vol.9, issue.3, pp.209-218, 1999. ,
DOI : 10.1023/A:1008922030873
Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics, Statistics in Medicine, vol.26, issue.6, pp.2623-2639, 2002. ,
DOI : 10.1002/sim.1041
The 2nd phase slope of HCV decline is highly predictive of sustained virologic response following consensus IFN treatment for chronic hepatitis C and is determined by genotype but not dose, Hepatology, vol.32, p.356, 2000. ,
Bayesian analysis of a population HIV dynamic model. Case studies in Bayesian, statistics, vol.6, pp.223-237, 2002. ,
Bayesian Experimental Design for Nonlinear Mixed-Effects Models with Application to HIV Dynamics, Biometrics, vol.50, issue.1, pp.25-33, 2004. ,
DOI : 10.1038/373117a0
Estimation of dynamical model parameters taking into account undetectable marker values, BMC Medical Research Methodology, vol.49, issue.1, pp.1-10, 2006. ,
DOI : 10.1111/1467-9876.00207
Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics, Journal of Theoretical Biology, vol.267, issue.3, pp.330-340 ,
DOI : 10.1016/j.jtbi.2010.08.036
Design Optimization in Nonlinear Mixed Effects Models Using Cost Functions: Application to a Joint Model of Infliximab and Methotrexate Pharmacokinetics, Communications in Statistics - Theory and Methods, vol.34, issue.18, pp.3351-3368, 2009. ,
DOI : 10.1177/0962280206079018
URL : https://hal.archives-ouvertes.fr/inserm-00424247